Use of a sesquiterpene polyketide compound for preventing and treating pulmonary hypertension
Through the sesquiterpene polyketone compounds isolated from the fungus of the genus genus, the problem that existing drugs cannot reverse pulmonary vascular remodeling is solved, and effective treatment of pulmonary hypertension is achieved, which significantly improves the patient's survival and quality of life.
Patent Information
- Application Number
- CN202210626231.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-02
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-06-02
AI Technical Summary
Existing drugs for treating pulmonary hypertension cannot effectively reverse pulmonary vascular remodeling, resulting in poor prognosis in patients and difficult to effectively improve treatment.
Sesquiterpene polyketone compounds were isolated and identified from fungi of the genus genus, separated by microbial fermentation and chromatography, and prepared into pharmaceutical compositions for the treatment of pulmonary hypertension, including its pharmaceutically acceptable salts and carriers for reverse Pulmonary vascular remodeling.
This compound can significantly reverse pulmonary vascular remodeling, improve symptoms related to pulmonary hypertension, and improve patient survival, providing a new effective drug for the treatment of pulmonary hypertension.
Smart Images

Figure CN114796171B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of natural medicines, and specifically relates to the use of a sesquiterpene polyketone compound for preventing and treating pulmonary hypertension. Background Art
[0002] Pulmonary hypertension (PH) is a large class of malignant pulmonary vascular diseases characterized by increased pulmonary artery pressure with or without pulmonary arteriole lesions. Its prognosis is similar to that of many advanced cancers. Its main feature is the progressive increase in pulmonary vascular resistance, which eventually leads to right heart failure and death. [1] PH is a major global health problem. The latest data show that the prevalence of PH is about 1% of the global population and can reach 10% in people over 65 years old. [2] The complex etiology and difficult treatment are the main reasons for the long-term slow development of this field. Pulmonary vascular remodeling is the most important pathological feature of PH. [3] Currently, targeted drugs for the treatment of PH in clinical practice mainly play a role in pulmonary vasodilation and cannot effectively reverse pulmonary vascular remodeling. They can improve the quality of life of patients to a certain extent, but the prognosis of patients is still very poor, with a 3-year survival rate of about 68-70%. [4] PH is still a progressive and fatal disease. The fundamental reason why it is difficult to treat is that it is impossible to effectively reverse pulmonary vascular remodeling. Therefore, it is urgent to develop drugs that can effectively reverse pulmonary vascular remodeling. Summary of the invention
[0003] The purpose of the present invention is to provide a use of a sesquiterpene polyketone compound for preventing and treating pulmonary hypertension. Specifically, the inventor discovered, isolated and identified a sesquiterpene polyketone compound from a strain of the genus Myrocera, which has a significant effect in treating pulmonary hypertension.
[0004] The first aspect of the present invention provides a sesquiterpene polyketone compound or a pharmaceutically acceptable salt thereof for use in treating pulmonary hypertension, wherein the sesquiterpene polyketone compound is represented by formula (I):
[0005]
[0006] Furthermore, the pharmaceutically acceptable salt is a salt formed by the compound of formula (I) and an organic base or an inorganic base.
[0007] Furthermore, the formed salt is a sodium salt, a potassium salt, a calcium salt, a ferric salt, a magnesium salt, a zinc salt, an aluminum salt, a barium salt or an ammonium salt.
[0008] The second aspect of the present invention provides a method for preparing the above compound, comprising: fermenting the sesquiterpene polyketone compound shown in formula (I) by a microorganism, and then separating the sesquiterpene polyketone compound by chromatography to obtain the compound.
[0009] Furthermore, the microorganism is a fungus of the genus Mycorrhiza.
[0010] Further optionally, the Mycorrhiza fungus is ZLW0801-19, and its preservation number is CGMCC No.19039.
[0011] The third aspect of the present invention provides a pharmaceutical composition for treating pulmonary hypertension, comprising the above-mentioned sesquiterpene polyketide compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0012] Further optionally, the salt is any one of sodium salt, potassium salt, calcium salt, iron salt, magnesium salt, zinc salt, aluminum salt, barium salt and ammonium salt.
[0013] Further optionally, in one embodiment, the amount of the active ingredient (i.e., the compound of the present invention) contained in the pharmaceutical composition can be specifically used according to the patient's condition and the doctor's diagnosis, and the amount or concentration of the active compound can be adjusted within a wider range. The content of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 1-90% by weight of the composition.
[0014] Further optionally, the pharmaceutically acceptable carrier includes diluents, lubricants, binders, disintegrants, stabilizers, solvents, etc. The diluents of the present invention include but are not limited to starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, glucose, etc.; the lubricants include but are not limited to magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxam, etc.; the binders include but are not limited to water, ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the disintegrants include but are not limited to starch effervescent mixtures, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the stabilizers include but are not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ethers and carboxymethyl chitosan, etc.; the solvents include but are not limited to water, balanced salt solutions, etc.
[0015] Further optionally, the pharmaceutical composition is an oral preparation or an injection; preferably, the oral preparation includes but is not limited to any one of ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, pills, powders, oral liquids or emulsions; preferably, the injection is selected from any one of small water injections, infusions or lyophilized powder injections.
[0016] Beneficial Effects
[0017] The compound of formula (I) described in the present invention is derived from microbial fermentation, which is convenient for large-scale fermentation and industrial preparation; activity tests have found for the first time that the compound can reverse pulmonary vascular remodeling and has a significant effect in treating pulmonary hypertension. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 It is shown that the compound of formula (I) improves the weight loss of mice with hypoxia-induced pulmonary hypertension ( Figure 1 A) and increased right ventricular systolic pressure (RVSP) Figure 1 B); The results of lung tissue pathological analysis showed that the compound of formula (I) reduced the percentage of medial thickness of pulmonary arterioles at all levels and improved the degree of remodeling of pulmonary arterioles at all levels ( Figure 1 C).
[0019] Figure 2 It is shown that the compound of formula (I) has no significant effect on the weight loss of MCT-PH rats ( Figure 2 A); The compound of formula (I) improves the increase of RVSP in rats with pulmonary hypertension induced by MCT ( Figure 2 B) and the increase in the percentage of medial thickness (%MT) of pulmonary arterioles at all levels ( Figure 2 C). DETAILED DESCRIPTION
[0020] The present invention will be further illustrated below. It should be noted that the examples illustrate some preparation or use methods, however, it should be understood that these examples do not limit the present invention. The scope of protection of the present invention shall be subject to the contents recorded in the attached claims.
[0021] In the following examples, the mass spectrometer is the LCQ-Advantage mass spectrometer produced by Finnigan, USA. The superconducting nuclear magnetic resonance instrument is Bruker AV-400. The silica gel GF254 for thin layer chromatography and the silica gel for column chromatography (200-300 mesh) are both products of Qingdao Ocean Chemical Plant. The reversed ODS filler 50μm is a product of Japan YMC Company. The medium and low pressure liquid chromatograph is a product of Shanghai Lisui Electronic Technology Co., Ltd. The chromatographic column used for liquid phase separation is Phenomenex Gemini C18 column (10.0×250mm, 5μm). The methanol used for liquid chromatography is chromatographically pure, the water is double distilled water, and the other reagents are all analytically pure.
[0022] The animal experimental data shown in the embodiment are expressed as mean ± standard error (Mean ± SEM). For comparison of the difference between two groups of data, Two-tailed Student's t test was used for analysis; for comparison of the difference between more than two groups of data, One-way Anova was used for analysis. Statistical differences are indicated as follows: * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, and ns represents no significant difference. In the data analysis of pulmonary vascular remodeling (% MT), ** represents P < 0.01, *** represents P < 0.001 (compared with the non-modeling group); ### represents P < 0.001 (compared with the modeling group).
[0023] Example 1 Large-scale fermentation of the fungus ZLW0801-19 and its sample pretreatment method
[0024] (1) The fungal strain ZLW0801-19 of the genus Mycorrhiza was cultured on a potato dextrose agar (PDA) slant at 25°C for 5 days. After activation on the PDA slant, it was inoculated into 4 conical flasks (250 mL) containing PDB medium to prepare the seed solution. Each conical flask contained 100 mL of potato dextrose (PDB) medium and was cultured at 25°C for 5 days at a speed of 200 rpm to prepare the seed solution. Fermentation was carried out in 24 conical flasks (500 mL), each of which contained 70 g of rice. First, distilled water (105 mL) was added to each conical flask, the rice was soaked overnight, and then autoclaved at 120°C for 30 minutes. After cooling to room temperature, 5 mL of seed solution was inoculated into each conical flask and cultured at room temperature in the dark for 51 days.
[0025] (2) The fermented product was added to ethyl acetate for soaking extraction three times, and the extract was concentrated to dryness under reduced pressure to obtain a crude extract (81.7 g).
[0026] Example 2 Preparation of the compound of formula (I)
[0027] In Example 1, the crude ethyl acetate extract (81.7 g) was chromatographed on a silica gel column, eluted with cyclohexane-ethyl acetate (100:0, 98:2, 95:5, 90:10, 80:20, 70:30, 50:50, 0:100, v / v) and methanol in sequence, with each gradient elution volume of 6 L, to obtain 7 fraction samples (F1-F7). Fraction F6 was chromatographed on a medium- and low-pressure liquid phase ODS column, eluted with methanol-water (60:40, 70:30, 80:20, 90:10, 100:0, v / v) in sequence, with each gradient elution volume of 2.5 L, to obtain 7 fraction samples (F6.1-F6.7). Fraction F6.4 was subjected to medium-low pressure liquid phase ODS column chromatography, eluted with methanol-water (70:30, v / v), and the elution volume was 0.7 L to obtain 5 fraction samples (F6.4.1-F6.4.5). Fraction F6.4.2 (1630 mg) was prepared by reverse phase preparative HPLC (Phenomenex, Packed C18 column), and eluted with methanol-water (70:30, v / v) at a flow rate of 8 mL / min to obtain the compound of formula (I) (t R :35.2min,820mg).
[0028] The physicochemical constants are as follows:
[0029] Compound of formula (I): pale yellow solid; (c 1.0,CH3OH); UV(CH3OH)λ max (logε)206(4.43), 225(4.35),240(4.18),299(4.31)nm; IR(KBr)ν max 3146,2969,2929,2881,1621,1625,1448, 1258cm -1 ;ESI-MS(positive)m / z 389[M+H] + ,411[M+Na] + ;ESI-MS(negative)m / z 387[M– H] – ,775[2M–H] – ;HR-ESI-MS(positive)m / z 389.2331[M+H] + (calcd.forC 23 H 33 O5,389.2328), the molecular formula of the compound is determined to be C 23 H 32 O5; 1 H and 13 C NMR see Table 1.
[0030] Table 1 Compounds of formula (I) 13 C NMR and 1 H NMR data and assignments
[0031] No. <![CDATA[δ C ]]> <![CDATA[δ H ]]> No. <![CDATA[δ C ]]> <![CDATA[δ H ]]> 1 116.3,CH 4.87 13 <![CDATA[25.2,CH3]]> 0.95,s 2 <![CDATA[31.6,CH2]]> 1.73,Ha 14 <![CDATA[14.8,CH3]]> 0.59,s 1.70,Hb 15 <![CDATA[22.8,CH3]]> 0.90,s 3 71.5,CH 3.31 1' <![CDATA[59.8,CH2]]> 4.71,d(3.4) 4 36.9,C 2' 145.4,C 5 43.7,CH 2.45 3' 107.2,CH 6.50,s 6 <![CDATA[26.7,CH2]]> 1.79,Ha 4' 164.6,C 1.11,Hb 5' 111.3,C 7 <![CDATA[30.3,CH2]]> 1.52,Ha 6' 164.8,C 1.50,Hb 7' 110.2,C 8 42.8,CH 1.28 8' 193.5,CH 9.96,s 9 43.7,C OH-3 4.15,d(4.4) 10 143.0,C OH-1' 5.38,t(3.4) 11 <![CDATA[23.3,CH2]]> 2.63,d(12.8),Ha OH-4' 10.56,br.s 2.49,d(12.8),Hb OH-6' 12.79,s 12 <![CDATA[17.2,CH3]]> 1.02,d(6.7)
[0032] The data recorded in DMSO-d6( 1 H NMR for 300MHz, 13 C NMR for 75MHz)
[0033] Example 3 The compound of formula (I) has a protective effect on the hypoxic pulmonary hypertension model (mice)
[0034] The hypoxic pulmonary hypertension mouse model was established by the normobaric continuous hypoxia method. C57BL / 6 male mice aged 8 weeks and weighing 20-25g were selected and used for the experiment after acclimating to the environment for 3 days. The mice were exposed to the hypoxic chamber for 4 weeks, in which the O2 concentration was maintained at 10% and the CO2 concentration was maintained below 5%. The cabin door was opened and cleaned every 2 days, the bedding was replaced, and mouse food and drinking water were added. The water vapor in the cabin was absorbed by anhydrous calcium chloride. 12 hours of light / 12 hours of darkness were given every day. The temperature in the cabin was maintained at 20-25℃. Except for inhaling air, the normoxic control group had the same conditions as the hypoxic group.
[0035] Male C57BL / 6 mice were divided into 3 groups, and the treatments of each group were as follows: normoxic group (N4W): mice were raised under normoxic environment for 4 weeks, and the solvent was intraperitoneally injected twice a week, for a total of 8 times, n=8; hypoxic group (H4W): mice were raised under hypoxic environment for 4 weeks, and the solvent was intraperitoneally injected twice a week, for a total of 8 times, n=8; hypoxic + Formula (I) compound treatment group (H4W+Formula I): mice were raised under hypoxic environment for 4 weeks, and 20 mg / kg Formula (I) compound was intraperitoneally injected twice a week, for a total of 8 times, n=9.
[0036] The changes of body weight, right ventricular systolic pressure (RVSP, reflecting the pulmonary artery pressure of mice) and pulmonary vascular remodeling (the percentage of vascular wall media thickness to vascular outer diameter, %MT) were observed.
[0037] Specific results such as Figure 1 As shown: The compound of formula (I) can improve the effect of hypoxia on the body weight of mice ( Figure 1 A); After exposure to a hypoxic environment, the RVSP of the mice in the hypoxic group increased significantly compared with the normoxic group, and the RVSP of the mice in the hypoxic group decreased after intraperitoneal injection of the compound of formula (I) compared with the hypoxic group ( Figure 1B); Compared with the normoxic group, the percentage of media thickness (%MT) of the pulmonary arterioles at all levels in the hypoxic group mice was significantly increased, and the media was significantly thickened, that is, obvious hypoxic pulmonary vascular remodeling occurred, and the remodeling degree of the pulmonary arterioles at all levels was improved after treatment with the compound of formula (I) ( Figure 1 C). The above results suggest that the compound of formula (I) can reverse the severity of pulmonary vascular remodeling and prevent the formation of hypoxia-related pulmonary hypertension.
[0038] Example 4 The compound of formula (I) has a protective effect on the pulmonary hypertension model (rat) induced by monocrotaline (MCT)
[0039] A rat model of pulmonary hypertension was established by a single intraperitoneal injection of MCT (60 mg / kg).
[0040] Male SD rats were divided into 3 groups, and the treatments of each group were as follows: control group (Control): intraperitoneal injection of solvent, 2 times / week, 8 times in total, n=3; MCT group (MCT): starting from the first day of MCT injection, intraperitoneal injection of solvent, 2 times / week, 8 times in total, n=4; MCT+Formula (I) treatment group (MCT+Formula I): starting from the first day of MCT injection, intraperitoneal injection of 20 mg / kg Formula (I) compound / time, 2 times / week, 8 times in total, n=4.
[0041] The changes of body weight, right ventricular systolic pressure (RVSP, reflecting the pulmonary artery pressure of rats) and pulmonary vascular remodeling (the percentage of vascular wall media thickness to vascular outer diameter, %MT) were observed.
[0042] Specific results such as Figure 2 As shown: The compound of formula (I) had no significant effect on the weight loss of MCT-PH rats ( Figure 2 A); however, compared with the control group, the RVSP of the rats in the MCT group increased significantly, and the RVSP of the rats after intraperitoneal injection of the compound of formula (I) decreased compared with the MCT group ( Figure 2 B); Compared with the control group, the percentage of media thickness (%MT) of pulmonary arterioles at all levels in the MCT group was significantly increased, and the media thickened significantly, that is, obvious pulmonary vascular remodeling occurred, and the remodeling degree of pulmonary arterioles at all levels was improved after treatment with the compound of formula (I) ( Figure 2 C). The above results suggest that the compound of formula (I) can reverse the severity of pulmonary vascular remodeling and prevent the formation of MCT-induced pulmonary hypertension.
[0043] The results of Examples 3 and 4 indicate that the compound of formula (I) has a protective effect on animal models of pulmonary hypertension and can be used for the treatment of pulmonary hypertension.
[0044] References:
[0045] [1]Galie,N.,et al.,2015 ESC / ERS Guidelines for the diagnosis andtreatment of pulmonary hypertension:The Joint Task Force for the Diagnosisand Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS):Endorsed by:Association forEuropean Paediatric and Congenital Cardiology(AEPC),International Society forHeart and Lung Transplantation(ISHLT).Eur Heart J,2016.37(1):67-119.
[0046] [2]Hoeper,M.M.,et al.,A global view of pulmonary hypertension.LancetRespir Med,2016. 4(4):306-22.
[0047] [3]Tuder,R.M.,Pulmonary vascular remodeling in pulmonaryhypertension.Cell Tissue Res, 2017.367(3):643-649.
[0048] [4]Farber,H.W.,et al.,Five-Year outcomes of patients enrolled in theREVEAL Registry.Chest, 2015.148(4):1043-1054.
Claims
1. Use of a sesquiterpene polyketide compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating pulmonary hypertension, characterized in that: The sesquiterpene polyketone compound is shown in formula (I): (I)。 2. The use according to claim 1, characterized in that The pharmaceutically acceptable salt is a salt formed by the compound of formula (I) and an organic base or an inorganic base.
3. The use according to claim 2, characterized in that: The formed salt is a sodium salt, a potassium salt, a calcium salt, a ferric salt, a magnesium salt, a zinc salt, an aluminum salt, a barium salt or an ammonium salt.
